ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
126.526,27
1,51%
S&P 500
5.099,96
1,02%
US Dollar vs BRL
5,1163
0,00%
Bitcoin
63.120,42
-0,97%
Brent Oil
88,165
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. XOMA Corporation (XOMA)

  7. XOMA Corporation (XOMA) Notícias

XOMA

XOMA (XOMA)

XOMA Corporation
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:XOMA
DataHoraFonteTítuloCódigoCompanhia
25/04/202408:30GlobeNewswire Inc.XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)NASDAQ:XOMAXOMA Corporation
24/04/202410:00PR Newswire (US)Actym Therapeutics Appoints Thomas Smart as CEONASDAQ:XOMAXOMA Corporation
03/04/202410:00GlobeNewswire Inc.XOMA Corporation Announces Closing of Tender OfferNASDAQ:XOMAXOMA Corporation
21/03/202408:30GlobeNewswire Inc.XOMA Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAXOMA Corporation
19/03/202417:05GlobeNewswire Inc.XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.NASDAQ:XOMAXOMA Corporation
08/03/202409:30GlobeNewswire Inc.XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder ValueNASDAQ:XOMAXOMA Corporation
28/02/202409:30GlobeNewswire Inc.XOMA to Present at Upcoming Investor Conferences in MarchNASDAQ:XOMAXOMA Corporation
16/02/202410:00GlobeNewswire Inc.XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value RightNASDAQ:XOMAXOMA Corporation
18/01/202410:30GlobeNewswire Inc.XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® AcquisitionNASDAQ:XOMAXOMA Corporation
11/01/202418:50Dow Jones NewsXoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for ArimoclomolNASDAQ:XOMAXOMA Corporation
11/01/202418:05GlobeNewswire Inc.FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRxNASDAQ:XOMAXOMA Corporation
08/01/202409:30GlobeNewswire Inc.XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of DirectorsNASDAQ:XOMAXOMA Corporation
02/01/202409:30GlobeNewswire Inc.XOMA Announces Stock Repurchase Program of up to $50 MillionNASDAQ:XOMAXOMA Corporation
19/12/202309:30GlobeNewswire Inc.XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® RoyaltiesNASDAQ:XOMAXOMA Corporation
07/11/202309:30GlobeNewswire Inc.XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder ValueNASDAQ:XOMAXOMA Corporation
31/10/202308:30GlobeNewswire Inc.XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)NASDAQ:XOMAXOMA Corporation
06/09/202308:30GlobeNewswire Inc.XOMA to Present at H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:XOMAXOMA Corporation
08/08/202308:30GlobeNewswire Inc.XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization StrategyNASDAQ:XOMAXOMA Corporation
23/06/202319:14GlobeNewswire Inc.XOMA Added to the Russell 2000® and Russell 3000® IndexesNASDAQ:XOMAXOMA Corporation
22/06/202308:30GlobeNewswire Inc.XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology AssetNASDAQ:XOMAXOMA Corporation
25/05/202317:34Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XOMAXOMA Corporation
18/05/202318:23Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:XOMAXOMA Corporation
09/05/202308:36Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XOMAXOMA Corporation
09/05/202308:30GlobeNewswire Inc.XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization StrategyNASDAQ:XOMAXOMA Corporation
26/04/202308:30GlobeNewswire Inc.XOMA to Present at H.C. Wainwright BioConnect Investor ConferenceNASDAQ:XOMAXOMA Corporation
04/04/202317:20Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:XOMAXOMA Corporation
30/03/202308:30GlobeNewswire Inc.XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone PortfolioNASDAQ:XOMAXOMA Corporation
09/03/202309:45Edgar (US Regulatory)Annual Report (10-k)NASDAQ:XOMAXOMA Corporation
09/03/202309:30GlobeNewswire Inc.XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization StrategyNASDAQ:XOMAXOMA Corporation
28/02/202309:30GlobeNewswire Inc.XOMA to Present at 43rd Annual Cowen Health Care ConferenceNASDAQ:XOMAXOMA Corporation
 Apresentando as notícias mais relevantes sobre:NASDAQ:XOMA

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
MATD3
Hospital Mater Dei S.A ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
GOLL4
GOL PN
BOV
HOOT4
HOTEIS OTHON PN
BOV
UNIP6
UNIPAR PNB
BOV
PDGR3
PDG REALT ON
BOV
OIBR3
OI ON
BOV
PDTC3
Padtec ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados